Poland· PL-100539557
IMDYLLTRA
A other monoclonal antibodies and antibody drug conjugates product containing tarlatamabum, registered in Poland by Amgen Europe B.V.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tarlatamabum is registered in 5 of 19 countries.
Countries holding a registration under ATC L01FX (other monoclonal antibodies and antibody drug conjugates), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Tarlatamabum · ATC L01FX
5 / 19 countries
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Tarlatamabum
- Manufacturer
- Amgen Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01FX
- ATC class
- Other monoclonal antibodies and antibody drug conjugates
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin08715131032098
- gtin04150201905119
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tarlatamabum in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumImdylltra 10 mgAmgen Europe
- SwitzerlandImdylltra 10 mg, Pulver für ein Konzentrat und Stabilisatorlösung zur Herstellung einer InfusionslösungAmgen Switzerland AG
- SpainIMDYLLTRA 10 MG POLVO PARA CONCENTRADO Y SOLUCION PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandImdylltraAmgen Europe B.V.
- United KingdomImdylltra 10mg powder for concentrate and solution for solution for infusion vialsAmgen Ltd
- IcelandImdylltraAmgen Europe B.V.*
- NorwayImdylltraAmgen Europe B.V.
- SwedenIMDYLLTRA 10 mg Pulver till koncentrat och lösning till infusionsvätska, lösningAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imdylltra
- Norway · Imdylltra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/88b465b5-2c27-4830-af1f-b462e748faad GET /v1/drugs/88b465b5-2c27-4830-af1f-b462e748faad?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do koncentratu i roztwór, do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg",
"packaging": "04150201905119 ¦ Rpz ¦ EU/1/26/2033/002 ¦ 167387\n1 fiol. 10 mg proszku ¦ 1 fiol. 7 ml stabilizatora\n¦ UR/Z/4b/158/26 - 04150201905119",
"substance": "Tarlatamabum 10 mg",
"common_name": "Tarlatamabum",
"pl_product_id": "100539557",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tarlatamabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.